Current Beat
Nov | 19 | 2026
Press Release
Remix Therapeutics™ Announces Updated Positive REM-422 Phase 1 Data in Adenoid Cystic Carcinoma at 2026 EORTC-NCI-AACR Symposium
Late-breaking presentation highlights durable clinical activity, including 57% overall response rate at recommended Phase 2 dose in biomarker-positive patients Time on REM-422 treatment reached up to two years and remains ongoing, supporting potential for long term dosing Watertown, Mass., November 19, 2026 – Remix Therapeutics, Inc., a clinical-stage biotechnology company developing small molecule therapies to […]
Jun | 24 | 2026
Press Release
Passage Bio and Remix Therapeutics™ Announce Merger Agreement
Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin Remix’s lead program, REM-422, is an orally available mRNA degrader targeting MYB, a historically undruggable transcription factor implicated across multiple cancers Concurrent oversubscribed $100 million private placement […]
Mar | 19 | 2026
Press Release
Remix Therapeutics Granted FDA Fast Track Designation for REM-422 for the Treatment of Recurrent, Metastatic or Unresectable Adenoid Cystic Carcinoma
Preliminary Phase 1 Study Results Show Strong Anti-Tumor Activity and Favorable Safety Profile for First-in-Class Small Molecule MYB mRNA Degrader No Approved Treatment Options for Patients with MYB-Driven Solid Tumor Adenoid Cystic Carcinoma WATERTOWN, Mass., March 19, 2026 – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing […]
It's Sound Science